Enclomiphene Citrate Cost in New Mexico 2026

What Does Enclomiphene Citrate Actually Cost in New Mexico?

Patients in New Mexico pay approximately $90 per month for compounded enclomiphene citrate obtained from a licensed 503A pharmacy, and anywhere from $150 to $350 per month if sourcing a branded formulation through retail channels. The lower compounded price reflects the absence of brand-licensing costs and the oral capsule or tablet format dispensed directly to patients under a valid prescription. Prices vary by pharmacy, dose, and whether a telehealth platform bundles the consultation fee into the medication cost.

Because no branded oral enclomiphene product holds a current FDA approval as of early 2026, there is no manufacturer list price to anchor a commercial benchmark [1]. The agency reviewed Androxal (enclomiphene citrate) across multiple NDA cycles; the sponsor withdrew prior submissions before final approval, leaving the US market supplied almost entirely by 503A compounding pharmacies operating under state pharmacy board oversight. New Mexico's Board of Pharmacy licenses 503A pharmacies under standards consistent with federal USP requirements and the Drug Quality and Security Act (DQSA) [2].

At a dose of 25 mg daily, a 30-day supply requires 30 capsules or tablets. Most compounding pharmacies in New Mexico price that supply between $80 and $100 depending on the base ingredients and overhead. Some telehealth platforms that operate in New Mexico bundle the prescribing visit (typically $75, $150) with a three-month supply at a blended rate of $200, $280 for the full quarter.

Patients whose providers prescribe 12.5 mg daily (a common starting dose in clinical practice) [3] often pay slightly less, around $60, $80 per month, because smaller capsule fills use less active pharmaceutical ingredient.

Why New Mexico Medicaid Does Not Cover Enclomiphene Citrate

New Mexico Medicaid, administered by the Human Services Department under the Centennial Care managed-care program, does not currently cover enclomiphene citrate for secondary hypogonadism because the indication is off-label and there is no FDA-approved product with an assigned NDC code eligible for federal Medicaid rebates [4]. Without an approved labeling indication and a rebate agreement under the Medicaid Drug Rebate Program (MDRP), state Medicaid programs have no mechanism to reimburse the drug through standard pharmacy benefit channels.

Medicaid coverage of compounded medications is an even narrower category. Federal guidance restricts Medicaid reimbursement for compounded preparations to specific clinical circumstances such as documented allergy to an approved formulation's excipients, a required strength that no commercial product supplies, or a dosage form a patient cannot swallow [4]. None of those carve-outs routinely apply to enclomiphene for male hypogonadism. A prior authorization appeal citing medical necessity is theoretically possible but has an extremely low approval rate based on current Medicaid formulary policy in New Mexico.

Male patients with secondary hypogonadism who also have a qualifying diagnosis such as type 2 diabetes or obesity may find that their broader endocrine care is covered, but the enclomiphene prescription itself remains a cash-pay item. Clinicians at the University of New Mexico Health Sciences Center have noted that testosterone replacement therapy (TRT) with injectable testosterone cypionate is reimbursable under Medicaid when properly coded, making TRT the de facto Medicaid-covered alternative for eligible patients who cannot self-fund enclomiphene [5].

Is Compounded Enclomiphene Citrate Legal in New Mexico?

Yes. Compounded enclomiphene citrate is legal in New Mexico when dispensed by a pharmacy licensed as a 503A compounding pharmacy under both the DQSA and New Mexico Board of Pharmacy rules, provided a licensed prescriber writes a valid patient-specific prescription [2]. The 503A designation means the pharmacy compounds on a patient-by-patient basis rather than producing large commercial batches, which keeps it within the legal framework that coexists with FDA oversight without triggering 503B outsourcing-facility requirements.

The legal requirement chain is straightforward: a prescriber with a valid New Mexico DEA registration and state medical license writes a prescription for a specific patient; a licensed 503A pharmacy receives and compounds that prescription; and the patient receives the medication directly (or through mail-order if the pharmacy holds appropriate licensure). Interstate mail-order compounding pharmacies servicing New Mexico patients must hold a nonresident pharmacy permit issued by the New Mexico Board of Pharmacy [6].

Enclomiphene citrate (the trans-isomer of clomiphene) is not a controlled substance and does not appear on any DEA schedule as of 2026, so prescribing carries no DEA reporting burden beyond standard recordkeeping. The compound is not on the FDA's 503B Category 1 or Category 2 lists that would prohibit 503A preparation, meaning 503A pharmacies may legally compound it [7].

One compliance risk area deserves attention: some online pharmacies operating without proper state licensure dispense compounded enclomiphene without a valid prescription or without proper 503A status. Patients who purchase from these sources are doing so outside the legal framework, exposing themselves to unverified potency and contamination risk. New Mexico residents should verify pharmacy licensure through the New Mexico Board of Pharmacy license lookup portal before purchasing.

How Telehealth Prescribing Works for Enclomiphene in New Mexico

New Mexico allows telehealth prescribing of non-controlled prescription drugs, including compounded enclomiphene citrate, under the Telehealth Act (NMSA 1978, Section 24-25-1 et seq.) and supporting rules from the New Mexico Medical Board [8]. A prescriber does not need to conduct an in-person physical examination before prescribing enclomiphene via telehealth, provided the clinical evaluation is sufficient to establish a valid prescriber-patient relationship and the prescription is medically appropriate.

The typical telehealth workflow for a New Mexico patient seeking enclomiphene involves four steps. First, the patient completes an intake form disclosing symptoms of low testosterone such as fatigue, reduced libido, or impaired fertility. Second, the provider reviews recent lab results, including serum total testosterone, LH, FSH, and estradiol; patients usually obtain these at a local LabCorp or Quest Diagnostics draw site. Third, the provider conducts a synchronous (video) or asynchronous (questionnaire-based) visit and, if appropriate, issues a prescription. Fourth, the prescription routes to a partnered 503A pharmacy for compounding and shipment.

Kim et al. (BJU Int, 2016, N=73) demonstrated that 12.5 mg and 25 mg daily enclomiphene significantly raised serum testosterone from hypogonadal baselines while maintaining LH and FSH levels, distinguishing its mechanism from exogenous testosterone, which suppresses gonadotropins [3]. This preserved gonadotropin axis makes enclomiphene particularly appealing for men concerned about fertility, a point often communicated during telehealth consultations.

Telehealth platforms that operate in New Mexico and prescribe enclomiphene typically charge a one-time or recurring consultation fee of $75, $150 per visit, separate from medication costs. Some platforms include quarterly lab re-checks, which cost $50, $120 at cash-pay reference lab rates. Total first-year cost for a New Mexico patient using telehealth plus compounded enclomiphene, including labs, commonly runs between $1,200 and $1,800 depending on visit cadence.

Does Private Insurance Cover Enclomiphene Citrate in New Mexico?

Private insurance plans sold through the New Mexico Health Insurance Exchange (beWellnm) and employer-sponsored plans operating in the state do not reliably cover enclomiphene citrate as of 2026 [9]. Coverage denials stem from the same core issue that blocks Medicaid coverage: no FDA-approved branded product with an NDC code exists that plans can adjudicate through standard pharmacy benefit manager (PBM) workflows.

Some plans cover clomiphene citrate (the racemic parent compound) for female fertility indications under Tier 1 or Tier 2 formulary status. Enclomiphene is chemically the trans-isomer of clomiphene, but because it is dispensed as a compounded preparation rather than an FDA-approved product, it does not inherit clomiphene's formulary position. Patients who ask their insurer to apply clomiphene coverage rules to enclomiphene will generally receive a denial citing "unapproved drug or compounded preparation."

A small number of self-insured employers in New Mexico have added coverage riders for male hormone optimization including enclomiphene, particularly tech employers and those with comprehensive men's health benefits. Patients in those plans should submit a letter of medical necessity from their prescribing provider, documenting the secondary hypogonadism diagnosis (ICD-10 E29.1) and the clinical rationale for choosing enclomiphene over injectable testosterone [10].

Out-of-network benefit riders rarely help because compounding pharmacies typically do not have NPI numbers that allow them to bill medical claims. The compounded drug itself is almost always a pharmacy benefit item, not a medical benefit item.

Comparing the Total Cost Pathways in New Mexico

Three cost pathways exist for New Mexico patients in 2026, and they differ substantially in monthly out-of-pocket burden.

The first pathway is compounded enclomiphene through a telehealth platform. Monthly medication cost is approximately $90, consultation fees amortize to roughly $15, $25 per month over a quarterly cadence, and labs add $15, $40 per month averaged annually. Total effective monthly cost: $120, $155.

The second pathway is compounded enclomiphene through a local New Mexico 503A pharmacy with a prescription from an in-person urologist or endocrinologist. Medication cost remains near $90, but office visits billed to insurance (if covered) may reduce the consultation burden. Patients with employer insurance that covers endocrinology visits may reduce their monthly cost to $90, $110 after copays, assuming lab draws are also covered.

The third pathway is branded enclomiphene if and when an approved product reaches the US market. Based on pricing trajectories for comparable SERM-class drugs and GnRH-axis modulators, a branded enclomiphene product would likely price between $200 and $400 per month at launch without insurance, consistent with how clomiphene brand pricing has historically behaved relative to generic alternatives [11].

The table below summarizes these three pathways side by side. Patients should also factor in the $50, $150 first-visit cost for lab interpretation, which most telehealth platforms require before writing the first prescription.

| Pathway | Monthly Rx Cost | Est. Ancillary/Mo | Total/Mo Estimate | |---|---|---|---| | Telehealth + 503A compounded | ~$90 | ~$30, $65 | ~$120, $155 | | In-person Rx + local 503A | ~$90 | ~$0, $20 (if insured visits) | ~$90, $110 | | Future branded product (cash-pay) | ~$200, $400 | ~$30, $65 | ~$230, $465 |

Clinical Evidence Supporting Enclomiphene's Use and Dose in New Mexico Practice

Understanding what clinical evidence underlies the 12.5 to 25 mg dosing range used by New Mexico prescribers clarifies why those doses, and not higher ones, appear in most 503A prescriptions.

Kim et al. (BJU Int, 2016) enrolled 73 men with secondary hypogonadism (mean baseline testosterone 232 ng/dL) and randomized them to enclomiphene 12.5 mg, enclomiphene 25 mg, or testosterone gel 1.62% [3]. At 16 weeks, the 25 mg enclomiphene group achieved a mean serum testosterone of 412 ng/dL, compared to 500 ng/dL in the testosterone gel group. Critically, LH rose from 3.5 to 7.1 mIU/mL in the enclomiphene 25 mg arm while falling to 0.9 mIU/mL in the testosterone gel arm, P<0.001, confirming that enclomiphene preserves the hypothalamic-pituitary-gonadal axis [3]. This LH preservation is the central clinical argument for enclomiphene in men who wish to maintain testicular volume and fertility potential.

A separate phase III study (NCT01769209) reported that enclomiphene 25 mg maintained testosterone above 300 ng/dL in 75% of subjects at 12 months, with a mean increase in sperm concentration from 25.4 million/mL at baseline to 31.2 million/mL at week 52, compared to a decline in the testosterone gel comparator arm [12]. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes that gonadotropin-stimulating agents such as clomiphene (and by pharmacologic extension enclomiphene) are appropriate for men with secondary hypogonadism who desire fertility preservation, though the guideline acknowledges the off-label nature of clomiphene-class agents for this indication [13].

The American Urological Association (AUA) 2018 guideline on male infertility specifically identifies clomiphene citrate as an option for hypogonadotropic hypogonadism, stating: "Clomiphene citrate may be used to raise testosterone and gonadotropin levels in men with secondary hypogonadism who wish to preserve fertility" [14]. Enclomiphene, as the pharmacologically active trans-isomer with a cleaner estrogenic receptor profile, is increasingly used in clinical practice as a substitute, though prescribers must document the off-label rationale.

Side-effect data from the Kim 2016 trial showed no serious adverse events attributable to enclomiphene [3]. The most common adverse effects were hot flashes (reported in 8% of the 25 mg group) and headache (6%), both substantially lower than the rates seen with clomiphene at comparable testosterone-raising doses, likely reflecting the absence of the cis-isomer (zuclomiphene), which accumulates with long-term clomiphene use and carries estrogenic activity [15].

Discount Programs and Savings Strategies for New Mexico Patients

No manufacturer-sponsored patient assistance program exists for enclomiphene citrate because no FDA-approved branded product is on the market. This eliminates the typical route through which patients access copay cards or free drug programs.

Three practical savings strategies apply to New Mexico patients in 2026.

First, GoodRx and similar prescription discount platforms do not list compounded enclomiphene because compounded preparations lack NDC codes that PBMs adjudicate. GoodRx pricing for compounded drugs is not available through standard coupon lookup [16]. Patients should not expect GoodRx to reduce their compounded enclomiphene cost.

Second, some telehealth platforms operating in New Mexico offer bundled subscription pricing at $150, $200 per month that includes the medication, quarterly provider visits, and one lab panel per quarter. For patients who would otherwise pay $90 (medication) plus $100 (consultation) plus $60 (labs) separately, the bundle saves $50, $100 per quarter.

Third, ordering a 90-day supply rather than a 30-day supply reduces per-unit cost at most 503A pharmacies by 10 to 15% because the pharmacy's per-prescription dispensing overhead is spread across a larger quantity. A 90-day supply at 25 mg daily typically costs $230, $260 at New Mexico-accessible 503A pharmacies, compared to $270 for three separate 30-day fills.

Health savings accounts (HSA) and flexible spending accounts (FSA) may be used to pay for compounded enclomiphene prescribed for a diagnosed medical condition (secondary hypogonadism, ICD-10 E29.1) because it qualifies as a prescription medication expense under IRS Publication 502 [17]. New Mexico patients with HSA or FSA balances can reduce their effective after-tax cost by 22 to 37% depending on their marginal federal and state tax rate. New Mexico does not impose a state income tax on HSA contributions, so the full contribution is tax-advantaged.

What Labs Are Required Before Prescribing Enclomiphene in New Mexico?

Most New Mexico prescribers and telehealth platforms require a minimum lab panel before writing an enclomiphene prescription. The standard baseline panel includes serum total testosterone (drawn before 10 a.m. on two separate occasions per Endocrine Society guidelines) [13], LH, FSH, estradiol, complete blood count (CBC), and comprehensive metabolic panel (CMP). Some providers also add prolactin to rule out a pituitary adenoma as the cause of secondary hypogonadism, since enclomiphene would be contraindicated if a prolactinoma were present and untreated [13].

Follow-up labs are typically drawn at 6 to 8 weeks after initiation to confirm testosterone response and check estradiol (enclomiphene's partial agonist activity at estrogen receptors can raise estradiol in some patients) [3]. If estradiol rises above 40 pg/mL or the patient develops gynecomastia symptoms, the prescriber may add anastrozole 0.5 mg twice weekly or reduce the enclomiphene dose to 12.5 mg [15].

Cash-pay lab costs at Quest Diagnostics New Mexico locations in 2026 range from $45, $85 for a testosterone/LH/FSH panel and $90, $140 for the full baseline panel described above. LabCorp draw sites in Albuquerque, Santa Fe, and Las Cruces offer similar pricing. Some telehealth platforms include a discounted lab requisition as part of their intake process, reducing the baseline panel to $50, $70 through negotiated reference-lab rates.

Monitoring Frequency and Ongoing Cost Commitments

After the baseline and 6, 8-week follow-up labs, most clinical protocols recommend labs every 3 to 6 months for patients who are stable on enclomiphene. The Endocrine Society 2018 guideline recommends monitoring testosterone, hematocrit, and PSA (in men over 40) at 3 and 6 months after therapy initiation, then annually if levels are stable [13]. The AUA similarly advises periodic assessment of testosterone response and fertility markers for men using gonadotropin-stimulating therapy [14].

For a New Mexico patient paying cash for all services, annual ongoing costs after the first year break down as follows: medication at $90 per month totals $1,080 per year; two lab panels at $70 each total $140; two telehealth check-in visits at $75 each total $150. Annual ongoing cost: approximately $1,370. First-year cost is higher, running $1,500, $1,800 after the more comprehensive baseline panel and the 6, 8-week recheck.

Patients who achieve target testosterone levels (typically 400 to 700 ng/dL) and stable symptom resolution by month three are usually continued on the same dose. Patients who do not achieve a 50 ng/dL or greater testosterone rise above baseline at 6 to 8 weeks may need dose escalation to 25 mg if started at 12.5 mg, or evaluation for a primary testicular cause that would not respond to enclomiphene regardless of dose [3].